{"_id": "US10500001", "text": "Humanized anti-PD-1 monoclonal antibody and methods of use. The present invention relates to humanized monoclonal antibodies that specifically bind to human PD-1 (programmed death-1) receptor and methods of using such antibodies for treating cancer. The antibody comprises a heavy chain variable region with CDR sequences that provide high affinity binding to PD-1. Methods include treating melanoma, lung cancer, and other solid tumors by administering the anti-PD-1 antibody to enhance T cell anti-tumor activity.", "metadata": {"priority_date": "2017-03-15", "ipc_codes": ["A61K39/395", "C07K16/28"], "smiles": null, "sequence": "QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGEINPSNGGTNFNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGYSYGAFDIWGQGTMVTVSS"}}
{"_id": "US10500002", "text": "Bispecific antibody targeting CD3 and tumor antigen for cancer immunotherapy. A bispecific antibody construct that simultaneously binds to CD3 on T cells and a tumor-associated antigen to redirect T cell cytotoxicity against tumor cells. The construct comprises a first binding domain specific for CD3epsilon and a second binding domain specific for CD19, HER2, or EGFR. The bispecific antibody induces T cell activation and tumor cell lysis independent of MHC restriction.", "metadata": {"priority_date": "2016-08-22", "ipc_codes": ["C07K16/46", "A61K39/395"], "smiles": null, "sequence": "DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGGGTKVEIK"}}
{"_id": "US10500003", "text": "Small molecule inhibitor of PD-1/PD-L1 interaction for cancer treatment. The present invention provides small molecule compounds that inhibit the interaction between programmed death-1 (PD-1) and its ligand PD-L1. The compounds restore T cell function in the tumor microenvironment and enhance anti-tumor immunity. Pharmaceutical compositions and methods of treating cancer including melanoma and non-small cell lung cancer are disclosed.", "metadata": {"priority_date": "2017-06-10", "ipc_codes": ["A61K31/4439", "A61P35/00", "C07D401/04"], "smiles": "CC1=NC(=C(C=C1)C2=CN=C(N2)NC3=CC=C(C=C3)NC(=O)C4=CC=NC=C4)C", "sequence": null}}
{"_id": "US10500004", "text": "Chimeric antigen receptor T cell targeting CD19 for B-cell malignancies. The invention provides chimeric antigen receptor (CAR) constructs comprising an extracellular CD19-binding domain, a transmembrane domain, and intracellular signaling domains including CD3zeta and 4-1BB costimulatory domain. T cells expressing the CAR demonstrate potent cytotoxicity against CD19-positive B-cell tumors. Methods of manufacturing and administering CAR-T cells are provided.", "metadata": {"priority_date": "2015-11-30", "ipc_codes": ["C07K14/725", "A61K35/17", "C12N5/0783"], "smiles": null, "sequence": "MDWTWRILFLVAAATGAHSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIK"}}
{"_id": "US10500005", "text": "Anti-CTLA-4 antibody with enhanced effector function for cancer immunotherapy. A fully human monoclonal antibody that binds to CTLA-4 with high affinity and blocks interaction with B7 ligands. The antibody is engineered with mutations in the Fc region to enhance binding to activating Fc receptors and improve antibody-dependent cellular cytotoxicity against CTLA-4 expressing regulatory T cells in the tumor microenvironment.", "metadata": {"priority_date": "2016-04-18", "ipc_codes": ["C07K16/28", "A61K39/395"], "smiles": null, "sequence": "EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRHFGVPFDYWGQGTLVTVSS"}}
{"_id": "US10500006", "text": "Oncolytic herpes simplex virus encoding GM-CSF for cancer treatment. An attenuated herpes simplex virus type 1 engineered to selectively replicate in tumor cells and express granulocyte-macrophage colony-stimulating factor (GM-CSF). The virus causes direct tumor cell lysis and stimulates anti-tumor immune responses through GM-CSF-mediated dendritic cell recruitment and activation. Methods of treating melanoma by intratumoral injection are provided.", "metadata": {"priority_date": "2014-09-05", "ipc_codes": ["C12N7/00", "A61K35/763", "C12N15/869"], "smiles": null, "sequence": "MAPARSPSPLPLLLLLLWAVVASSAPARAPRQTCDDPPTTNASLLTKLQAQNRSLEPACRSLGSDSDPNQPF"}}
{"_id": "US10500007", "text": "LAG-3 targeting antibody for combination immunotherapy. The invention provides monoclonal antibodies that bind to lymphocyte activation gene-3 (LAG-3) and block its interaction with MHC class II molecules. The antibodies restore T cell function and synergize with PD-1 blockade for enhanced anti-tumor efficacy. Combination therapy methods for treating patients who have progressed on prior checkpoint inhibitor therapy are disclosed.", "metadata": {"priority_date": "2017-09-20", "ipc_codes": ["C07K16/28", "A61K39/395"], "smiles": null, "sequence": "QVQLQQSGAELARPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWIGAIYPGDGDTRYTQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARRGNYYGSSLDYWGQGTSVTVSS"}}
{"_id": "US10500008", "text": "Adenosine A2A receptor antagonist for cancer immunotherapy. Small molecule compounds that selectively inhibit the adenosine A2A receptor to overcome adenosine-mediated immunosuppression in the tumor microenvironment. The compounds enhance T cell and NK cell anti-tumor activity. Methods of treating cancer in combination with checkpoint inhibitors are provided.", "metadata": {"priority_date": "2018-01-12", "ipc_codes": ["A61K31/52", "C07D473/00", "A61P35/00"], "smiles": "CC1=NC2=C(N1C3=CC=CC=C3)N=CN(C2=O)CC4=CC=C(C=C4)OC", "sequence": null}}
{"_id": "US10500009", "text": "Anti-TIM-3 antibody for treatment of T cell exhaustion in cancer. Humanized monoclonal antibodies that bind to T cell immunoglobulin and mucin domain-3 (TIM-3) and block its interaction with galectin-9 and other ligands. The antibodies reverse T cell exhaustion in the tumor microenvironment and restore effector function. Combination with anti-PD-1 antibodies for treating refractory solid tumors is disclosed.", "metadata": {"priority_date": "2017-07-05", "ipc_codes": ["C07K16/28", "A61K39/395"], "smiles": null, "sequence": "EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSLISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRVPYYALDYWGQGTLVTVSS"}}
{"_id": "US10500010", "text": "Neoantigen cancer vaccine with personalized peptides. Methods and compositions for personalized cancer immunotherapy comprising identification of tumor-specific neoantigens through sequencing, prediction of immunogenic neoepitopes, and synthesis of peptide vaccines. The vaccine composition includes synthetic long peptides containing neoantigen sequences formulated with adjuvant for subcutaneous administration to elicit tumor-specific T cell responses.", "metadata": {"priority_date": "2016-12-08", "ipc_codes": ["A61K39/00", "A61K39/39", "C07K7/06"], "smiles": null, "sequence": "ELAGIGILTVILGVLLLIGCCKFPGFRVFRELHDNLLIVNPGNVYTITDKTVLDKRWFEPFQVTTGSAQ"}}
